| Trial ID: | L1917 |
| Source ID: | NCT03658031
|
| Associated Drug: |
Dapagliflozin 10mg
|
| Title: |
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
PreDiabetes|Myocardial Infarction|T2DM (Type 2 Diabetes Mellitus)|CVD
|
| Interventions: |
DRUG: Dapagliflozin 10mg
|
| Outcome Measures: |
Primary: Incidence rate of T2DM, T2DM in Myocardial patients with prediabetes, 36 months |
|
| Sponsor/Collaborators: |
Sponsor: Hamad Medical Corporation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
576
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-03-01
|
| Completion Date: |
2021-01-31
|
| Results First Posted: |
|
| Last Update Posted: |
2019-01-03
|
| Locations: |
Heart Hospital, Hamad Medical Coorporation, Doha, 3050, Qatar
|
| URL: |
https://clinicaltrials.gov/show/NCT03658031
|
